Bifogade filer
PDF
Kurs
+1,83%
Likviditet
1,40 MSEK
Kalender
| Tid* | ||
| 2025-11-04 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-19 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-12 | N/A | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2025-06-11 | N/A | Årsstämma |
| 2025-05-06 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-04 | - | Bokslutskommuniké 2024 |
| 2024-12-18 | - | Extra Bolagsstämma 2024 |
| 2024-11-12 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-06 | - | Bokslutskommuniké 2023 |
| 2023-11-21 | - | Kvartalsrapport 2023-Q3 |
| 2023-10-16 | - | Extra Bolagsstämma 2023 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-01 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2023-05-31 | - | Årsstämma |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-21 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-03 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2022-06-02 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-20 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2021-05-19 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-09 | - | Extra Bolagsstämma 2021 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-19 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-22 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2020-05-20 | - | Årsstämma |
| 2020-05-13 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
OssDsign AB (publ.) today announces that the company's current VP of Strategy, Business Development and Regulatory Affairs, Tom Buckland, has been appointed Chief Technical Officer (CTO). The promotion is a key part of the company's change of direction into a pure-play orthobiologics company focusing exclusively on the U.S. Market.
Tom Buckland, currently VP of Strategy, Business Development and Regulatory Affairs, will in his new role be responsible for Operations & Manufacturing, Research & Development as well as Quality Assurance and Regulatory Affairs.
"Since the Acquisition of Sirakoss in 2020, Tom Buckland has been an instrumental member of the team. Appointing him as our new CTO is an important step in OssDsign's transformation into a pureplay orthobiologics company. His scientific background combined with his vast operational experience from leading positions in spine and orthobiologics companies will be pivotal for the company's journey forward", said Morten Henneveld, CEO of OssDsign.
Tom Buckland joined OssDsign through the acquisition of Sirakoss, where he was the CEO. His previous experiences include leading positions at Nuvasive, Apatech and Baxter as well as working as a reputable advisor to start- and scale-up companies. Tom Buckland holds a Masters' degree in Mechanical Engineering and a Ph.D. in Biomaterials from the University of London.